Lab Automation: Everyone Re-invents the Wheel
March 2010. The molecular diagnostics industry is aiming at automation of the screening process spanning over three core steps: sample preparation, analysis, and detection. The Achilles’ heel of laboratory instrument development is a persisting lack of interconnectivity or cross-company standards which demanding customers require.
Big pharma customers are not anymore happy with suppliers’ marketing strategies of divide et impera – divide customers, fragment markets they are in, and conquer these. Michael Collasius, Vice President Automated Systems Qiagen NV, discussed with B2Bioworld the issues. With an addendum by Peer Michael Schatz.Reading time: 5 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Future Lab Work: Designing and Testing Environments
Laboratory Automation Standards... If users have to adopt it
Oscar-Werner Reif, CSO Sartorius Stedim
Handling Suppliers of Mass Spectrometers Delicately
A scientist’s strategy avoiding to get trapped by manufacturers of mass spectrometers with proprietary data formats
Thermo's BRIMS-Strategy Under Testing
Coping with Customers’ Response to Lock-in Tactics of Mass Spec-Manufacturers
Customs Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities